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OBJECTIVES: To estimate the prevalence of neuropsychi-
atric symptoms and examine their association with func-
tional limitations.
DESIGN: Cross-sectional analysis.
SETTING: The Aging, Demographics, and Memory Study
(ADAMS).
PARTICIPANTS: A sample of adults aged 71 and older
(N 5 856) drawn from Health and Retirement Study
(HRS), a nationally representative cohort of U.S. adults
aged 51 and older.
MEASUREMENTS: The presence of neuropsychiatric
symptoms (delusions, hallucinations, agitation, depression,
apathy, elation, anxiety, disinhibition, irritation, and aber-
rant motor behaviors) was identified using the Neuropsy-
chiatric Inventory. A consensus panel in the ADAMS
assigned a cognitive category (normal cognition; cognitive
impairment, no dementia (CIND); mild, moderate, or se-
vere dementia). Functional limitations, chronic medical
conditions, and sociodemographic information were ob-
tained from the HRS and ADAMS.
RESULTS: Forty-three percent of individuals with CIND
and 58% of those with dementia exhibited at least one
neuropsychiatric symptom. Depression was the most com-
mon individual symptom in those with normal cognition
(12%), CIND (30%), and mild dementia (25%), whereas
apathy (42%) and agitation (41%) were most common in
those with severe dementia. Individuals with three or more
symptoms and one or more clinically significant symptoms
had significantly higher odds of having functional limita-
tions. Those with clinically significant depression had
higher odds of activity of daily living limitations, and those
with clinically significant depression, anxiety, or aberrant
motor behaviors had significantly higher odds of instru-
mental activity of daily living limitations.
CONCLUSION: Neuropsychiatric symptoms are highly
prevalent in older adults with CIND and dementia. Of
those with cognitive impairment, a greater number of total
neuropsychiatric symptoms and some specific individual
symptoms are strongly associated with functional limita-
tions. J Am Geriatr Soc 58:330–337, 2010.
Key words: neuropsychiatric symptoms; cognitive impair-
ment; prevalence; functional status
Neuropsychiatric symptoms, such as agitation, depres-sion, apathy, delusions, and hallucinations, are highly
prevalent in older adults with dementia or milder forms of
cognitive impairment.1 These symptoms have important
implications for patients, families, and policymakers be-
cause they may be associated with greater caregiver dis-
tress,2,3 higher risk for functional decline,4–6 earlier
institutionalization,5–8 higher healthcare costs,9–12 and
greater mortality.5
A number of studies have examined the prevalence of
neuropsychiatric symptoms in clinical samples with cogni-
tive impairment.4,13–15 One reported that apathy, agitation,
and anxiety were the most common symptoms in those with
Alzheimer’s disease and that their prevalence was 72%,
60%, and 48%, respectively.15 Because clinical samples are
often subject to referral bias, these estimates may not apply
to cognitively impaired adults in nonclinical samples. Of
the few population-based studies reporting the prevalence
of neuropsychiatric symptoms, most have been conducted
on regional samples16–21 and have assessed individuals with
mild cognitive impairment (MCI) or dementia but did not
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include those with normal cognition.1,16,18,20,21 Most indi-
vidual neuropsychiatric symptoms were more prevalent
with increasing severity of cognitive impairment, whereas
some symptoms (e.g., delusions, depression, and anxiety)
were less frequent in those with severe dementia than in
those with moderate dementia.16,22 Studies on regional
samples may provide biased estimates of symptom
prevalence because of possible differences across regions
in sociodemographic and health characteristics of the
population.23
Studies examining an association between neuropsy-
chiatric symptoms and functional limitations have shown
mixed results and are difficult to interpret because of lack of
adjustment for co-occurring symptoms.4,24,25 In addition,
these studies may lack generalizability because of nonrep-
resentative samples in a clinical setting. Two studies using
regional samples found an association between the presence
of hallucinations and functional limitations.25,26
The goal of the current study was to estimate the prev-
alence of neuropsychiatric symptoms according to severity
of cognitive impairment (normal cognition; cognitive im-
pairment, no dementia (CIND); mild, moderate, and severe
dementia) using a population-based nationally representa-
tive sample of older adults in the United States. It was
hypothesized that neuropsychiatric symptoms would gen-
erally increase with increasing severity of cognitive impair-
ment but that symptom prevalence might be somewhat
lower in those with severe dementia and that the presence of
neuropsychiatric symptoms would be associated with more
limitations in basic activities of daily living (ADLs) or in-
strumental activities of daily living (IADLs), independent of
the level of cognitive impairment.
METHODS
Sample
Data from the Aging, Demographics, and Memory Study
(ADAMS) and the 2000 and 2002 waves of the Health and
Retirement Study (HRS) were used. The HRS is an ongoing
biennial longitudinal survey of a nationally representative
cohort of more than 20,000 U.S. adults aged 51 and older
who reside in the community and in nursing homes
throughout the 48 contiguous United States.27 The HRS
sample is selected using a multistage area probability sam-
ple design, and population weights are constructed so that
valid inferences can be drawn for the entire U.S. population
aged 51 and older. Weights are constructed in a two-step
process. The first step develops poststratified household
weights using the initial sampling probabilities for each
household, as well as birth year, race or ethnicity, and sex of
household members. The second step uses these household
weights to then construct poststratified respondent-level
weights that are scaled to yield weight sums corresponding
to the number of individuals in the U.S. population as mea-
sured by the U.S. Census Bureau’s Current Population Sur-
vey for the month of March in the year of data collection.28
The National Institute on Aging sponsors the HRS, which
the Institute for Social Research at the University of Mich-
igan conducts. The ADAMS is a substudy of the HRS fo-
cused on identifying the prevalence and outcomes of
cognitive impairment and dementia. The ADAMS sample
was a stratified random subsample of 1,770 individuals
aged 71 and older from five cognitive strata based on scores
for the 35-point HRS cognitive scale (HRS cog)29 or proxy
assessments of cognition from the 2000 or 2002 wave of the
HRS.30 The ADAMS further stratified the three highest
cognitive strata according to age (70–79 vs 80) and sex to
ensure adequate numbers in each subgroup.30
One hundred nine individuals (12.7%) in the ADAMS
sample resided in nursing homes at the time of the ADAMS
assessment. Population weights for nursing home residents
were derived using data from the 2000 Census and the
Centers for Medicare and Medicaid Services Minimum
Data Set.30 Full details of the ADAMS sample design and
selection procedures are described elsewhere.30–32 The ini-
tial assessments of the ADAMS subjects occurred between
July 2001 and December 2003, on average, 13.3  6.9
months after the most-recent HRS interview. The study
flow and additional details on participation rates have been
reported previously.32 A total of 856 individuals (mean age
81.5) received the initial ADAMS assessment. Sixteen in-
dividuals for whom the Neuropsychiatric Inventory (NPI)
was not completed (n 5 840 for current analyses) were not
included. To minimize the potential bias due to selective
nonparticipation, a response propensity analysis was per-
formed in the ADAMS, and nonresponse adjustments to the
ADAMS sample selection weights were developed.30 Pop-
ulation sample weights were then constructed to take into
account the probabilities of selection in the stratified sample
design and to adjust for differential nonparticipation in the
ADAMS.30
The ADAMS data are publicly available and can be
obtained from the HRS Web site (http://hrsonline.isr.umich.
edu). The institutional review boards at Duke University
Medical Center and the University of Michigan approved
all study procedures, and study participants or their surro-
gates provided informed consent.
Measurements
Cognitive Evaluation
In the ADAMS, a nurse and a neuropsychology technician
assessed all participants at their residence for cognitive im-
pairment. The full details of the assessment and diagnostic
procedures are described elsewhere.31,32 During the assess-
ment, participants completed a battery of neuropsycho-
logical measures, a self-reported depression measure, a
standardized neurological examination, a blood pressure
measurement, and collection of buccal deoxyribonucleic
acid samples for apolipoprotein E genotyping and watched
a 7-minute videotaped segment covering portions of the
cognitive status and neurological examinations. Proxy in-
formants provided information about the participant’s cog-
nitive impairment, functional limitations, neuropsychiatric
symptoms, and medical history. The informant was a
spouse or child in 73% of cases, and informants lived with
the participant in 53% of the cases. The ADAMS consensus
expert panel of neuropsychologists, neurologists, geropsy-
chiatrists, and internists reviewed all information collected
during the in-home assessment and assigned cognitive di-
agnoses. Diagnoses were within three cognitive categories:
normal cognitive function, CIND, and dementia. The Di-
agnostic and Statistical Manual of Mental Disorders, Third
Edition, Revised, and Fourth Edition criteria were used for
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diagnosis of dementia. CIND was defined as mild cognitive
or functional impairment reported by the participant or
informant that did not meet criteria for dementia or per-
formance on neuropsychological measures that was below
expectation and at least 1.5 SDs below published norms on
any test within a cognitive domain (e.g., memory, orienta-
tion, language, executive function, praxis).
Participants with dementia were classified according
the stage or severity using the Clinical Dementia
Rating (CDR) Scale,33–35 a widely used assessment tool
that stages the severity of dementia based on information
obtained from the participant and informant during the
course of the evaluation. As in prior studies,16,22 mild de-
mentia was defined as CDR stage 0.5 or 1.0, moderate
dementia as CDR stage 2.0, and severe dementia as CDR
stages 3.0 to 5.0.
Neuropsychiatric Symptoms
The ADAMS assessed neuropsychiatric symptoms using the
Neuropsychiatric Inventory (NPI). The NPI is a widely ac-
cepted measure of neuropsychiatric symptoms associated
with cognitive impairment.36 It collects information on
symptoms during the past month in 10 domainsFdelu-
sions, hallucinations, agitation, depression, anxiety, ela-
tion, apathy, disinhibition, irritability, and aberrant motor
behaviorsFusing a structured interview with a knowledge-
able informant. For each symptom reported by the infor-
mant, additional information is obtained on the frequency
(4-point scale), severity (3-point scale), and associated care-
giver distress (6-point scale) associated with the behavior.
Symptoms were defined as clinically significant if the prod-
uct of the frequency and severity score of the reported
symptom was 4 or higher.37 Psychometric properties of the
NPI have been previously reported.36 The NPI has been
validated in prior studies and has also been shown to have
good reliability (Cronbach alpha was 0.88 for internal con-
sistency reliability).36
Functional Limitations
The number of limitations in ADLs and IADLs was assessed
in the ADAMS using an informant questionnaire. The
ADLs assessed were getting across a room, dressing, bath-
ing, eating, transferring, and toileting. The IADLs assessed
were preparing meals, grocery shopping, making telephone
calls, taking medications, and handling finance. The num-
ber of difficulties was categorized using three ordinal levels
(0, 1 or 2, 3) for ADLs and IADLs.
Sociodemographic Characteristics
Data were obtained on participant age (71–79, 80–89,
90), sex, race (white, black, other), and years of formal
education (o12, 12, 412 years) from the ADAMS. House-
hold net worth was categorized according to quartile, and
marital and living status (married or partnered living to-
gether, unmarried living with other, unmarried living alone)
were determined using data from the 2000 and 2002 waves
of the HRS.
Chronic Medical Conditions
The HRS collects data on the presence of chronic medical
conditions (heart disease, chronic lung disease, diabetes
mellitus, cancer, musculoskeletal conditions, stroke, and
psychiatric problems) in each wave of the survey.38 Re-
spondents report whether a physician has ever diagnosed
each condition. Data on chronic conditions from the 2000
or 2002 wave of the HRS were used and included in the
analysis as dichotomous variables.
Statistical Analysis
Sociodemographic characteristics, cognitive category, and
chronic medical conditions were compared between those
without any neuropsychiatric symptoms, those with one or
two symptoms, and those with three or more symptoms
using chi-square tests. Using the ADAMS sample weights,
the prevalence of none, one to two, and three or more neu-
ropsychiatric symptoms and then the prevalence of each
individual neuropsychiatric symptom, stratified according
to cognitive category (normal cognition; CIND; mild, mod-
erate, or severe dementia), were computed.
Because one goal of the analysis was to identify
whether the presence of neuropsychiatric symptoms was
independently associated with a greater risk of functional
limitations, ordinal logistic regression models with ADL
and IADL limitations as the dependent variable were esti-
mated to examine whether total number of neuropsychiat-
ric symptoms was associated with functional limitations,
adjusting for sociodemographic factors, chronic medical
conditions, and cognitive category. Similar ordinal logistic
regression models were then estimated to examine whether
individual neuropsychiatric symptoms were associated
with functional limitations, adjusting for the presence of
co-occurring neuropsychiatric symptoms. Adjusted odds
ratios (ORs) were computed to compare the relative
strength of the association between each neuropsychiatric
symptom and functional limitations. To test the hypothesis
that level of cognitive impairment modifies the relationship
between neuropsychiatric symptoms and functional
limitations, significant interactions between cognitive
category and neuropsychiatric symptoms (e.g., total
number of neuropsychiatric symptoms by cognitive cate-
gory, the presence of delusions by cognitive category)
were tested for. None of these interaction terms was statis-
tically significant, so they were not included in the
final regression models. The analysis was repeated with
the variables for clinically significant neuropsychiatric
symptoms (frequency score times severity score 4), and
these results were compared with those from the previous
analyses for the presence or absence of any neuropsychiatric
symptoms.
It was verified that the proportional odds assumption
was not violated by checking for the same OR from two
logistic regression models that used different levels of ADL
or IADL limitations for dichotomizing the dependent vari-
able (0 vs 1 limitations; and 2 vs 3 limitations). The
proportional odds assumption was verified using the Score
test.39 All analyses were weighted and adjusted for the
complex sampling design (stratification, clustering, and
nonresponse) of the HRS and ADAMS. STATAversion 10.1
(Stata Corp, College Station, TX) was used for data anal-
ysis. All reported P values are two-tailed, and Po.05 was
considered statistically significant.
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RESULTS
Characteristics of the Study Sample
Table 1 shows the sociodemographic and clinical charac-
teristics of the study sample stratified according to the
number of neuropsychiatric symptoms (0, 1–2, 3).
Women, people with low net worth, and people living in
a nursing home were more likely to have neuropsychiatric
symptoms. CIND and dementia, as well as diabetes melli-
tus, heart disease, and stroke, were all associated with
greater risk for the presence of neuropsychiatric symptoms.
Prevalence of Neuropsychiatric Symptoms
Figure 1 shows the estimated prevalence of neuropsychiat-
ric symptoms for each of the cognitive categories. Gener-
Table 1. Sample Characteristics According to Number of Neuropsychiatric Symptoms
Characteristic
n (%)
P-ValueTotal 0 1 or 2 3
Sample (weighted %w) 840 (100.0) 518 (70.6) 202 (20.3) 120 (9.1)
Age .29
71–79 349 (58.9) 243 (61.4) 73 (53.8) 33 (51.1)
80–89 360 (34.0) 203 (32.3) 90 (38.6) 67 (36.9)
90– 131 (7.1) 72 (7.3) 39 (7.6) 20 (12.0)
Sex .003
Female 492 (60.6) 296 (61.0) 113 (51.4) 83 (78.5)
Male 348 (39.4) 222 (39.0) 89 (48.6) 37 (21.5)
Race .05
White 650 (89.7) 394 (88.9) 163 (93.5) 93 (87.5)
Black 157 (7.3) 104 (8.2) 31 (5.5) 22 (4.9)
Other 33 (3.0) 20 (2.9) 8 (1.0) 5 (7.6)
Education, years .03
o12 430 (33.4) 249 (31.3) 111 (40.1) 70 (34.9)
12 195 (29.2) 110 (27.2) 59 (37.2) 26 (26.8)
412 215 (37.4) 159 (41.5) 32 (22.7) 24 (38.3)
Household net worth quartile o.001
1 331 (25.2) 172 (19.5) 90 (31.3) 69 (55.7)
2 193 (22.0) 128 (22.3) 43 (23.8) 22 (15.9)
3 159 (24.6) 110 (27.3) 32 (18.3) 17 (17.5)
4 156 (28.2) 107 (30.9) 37 (26.6) 12 (10.9)
Cognitive category o.001
Normal cognition 303 (64.0) 258 (74.5) 37 (42.6) 8 (30.7)
Cognitive impairment, no dementia 238 (22.2) 151 (17.4) 64 (36.2) 23 (27.9)
Mild dementia 153 (7.6) 71 (5.8) 48 (11.5) 34 (12.9)
Moderate dementia 64 (2.5) 17 (0.8) 23 (3.7) 24 (12.3)
Severe dementia 82 (3.7) 21 (1.5) 30 (6.0) 31 (16.2)
Living situation o.001
Alone 270 (35.2) 181 (36.8) 53 (26.6) 36 (42.1)
With other 150 (12.8) 79 (11.2) 46 (18.9) 25 (11.3)
With spouse or partner 335 (46.9) 223 (49.4) 77 (46.5) 35 (28.3)
Nursing home 85 (5.1) 35 (2.6) 26 (8.0) 24 (18.3)
Chronic medical condition
Hypertension 494 (60.0) 301 (59.0) 115 (59.6) 78 (68.9) .34
Diabetes mellitus 172 (19.8) 95 (16.3) 55 (33.3) 22 (17.7) .004
Cancer 161 (19.3) 101 (19.3) 40 (19.3) 20 (19.4) 4.99
Lung disease 79 (8.5) 43 (6.5) 26 (14.4) 10 (10.5) .06
Heart disease 279 (30.1) 158 (24.7) 83 (41.0) 56 (46.8) o.001
Stroke 180 (15.5) 87 (13.6) 52 (16.1) 41 (29.2) .005
Psychiatric illnesses 170 (16.1) 64 (9.9) 56 (24.9) 50 (44.0) o.001
Arthritis 592 (70.6) 354 (68.5) 146 (72.6) 92 (82.5) .15
P-values were derived from the chi-square test for association between the indicated variable and the number of neuropsychiatric symptoms.
wPercentages are weighted percentages derived using the Aging, Demographics, and Memory Study (ADAMS) sample weights to adjust for the complex sampling
design of the ADAMS.
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ally, the presence of neuropsychiatric symptoms increased
with increasing severity of cognitive impairment. There was
a slightly lower prevalence of symptoms in those with se-
vere dementia than in those with moderate dementia, al-
though this difference was not statistically significant.
Figure 2 shows the estimated prevalence of each individual
neuropsychiatric symptom according to cognitive category.
Most neuropsychiatric symptoms were more common in
those with more-advanced cognitive impairment. Depres-
sion was the most common individual symptom in those
with normal cognition, CIND, and mild dementia (12% in
normal cognition, 30% in CIND, and 25% in dementia),
whereas apathy (42%), agitation (41%), and aberrant mo-
tor behaviors (31%) were the most common in those with
severe dementia. The proportion of clinically significant
symptoms (the shaded area in each graph, frequency score
by severity score 4) was higher in those with more severe
cognitive impairment for most neuropsychiatric symptoms.
Association with Functional Limitations
Table 2 shows the results of an ordinal logistic regression
for the association between neuropsychiatric symptoms
(e.g., total number of symptoms, individual symptoms) and
functional limitations in participants with CIND and de-
mentia. The first (ADL limitations) and third (IADL lim-
itations) columns of the table show the adjusted ORs for a
higher level of functional limitations in those presenting
with the neuropsychiatric symptoms than in those without
the symptoms. The model adjusts for other co-occurring
symptoms, cognitive category (e.g., CIND, mild, moderate,
or severe dementia), sociodemographic characteristics, and
chronic medical conditions. The second (ADL limitations)
and fourth (IADL limitations) columns of the table show
the adjusted ORs for a higher level of functional limitations
in those presenting with clinically significant symptoms
than in those without clinically significant symptoms. In-
dividuals with three or more neuropsychiatric symptoms
and one or more clinically significant symptoms had sig-
nificantly higher odds of ADL and IADL limitations. Those
with clinically significant depression had higher odds of
ADL limitations, and those with clinically significant de-
pression, anxiety, or aberrant motor behaviors had signifi-
cantly higher odds of IADL limitations. The analysis was
repeated after excluding those with CIND (i.e., an analysis
of only those with dementia), adjusting for dementia sever-
ity and the other covariates. The results were generally
similar to those obtained for the analysis of the combined
CIND–dementia group (data not shown).
DISCUSSION
In this study, the prevalence of neuropsychiatric symptoms
was estimated according to cognitive category, including
severity of dementia, using a nationally representative sam-
ple of older adults in the United States, and greater risk for
the presence of symptoms was found in those with more
advanced cognitive impairment. A greater number of neu-
ropsychiatric symptoms was independently associated with
functional limitations in those with CIND and dementia,
even after controlling for other potentially confounding
factors. Individual neuropsychiatric symptoms that were
most strongly associated with functional limitations in
those with CIND and dementia were also identified.
The prevalence estimates are comparable with prior
population-based estimates, after considering some meth-
odological differences.1,16,17 It was estimated that 57% of
those with dementia had at least one neuropsychiatric
symptom, which was nearly identical to a prior study that
used a similar methodology (56.2%)17 but lower than an-
other study (74.6%),1 probably because two additional
common symptoms (sleep difficulties and appetite or eating
problems) were included. The estimate of the prevalence of
any neuropsychiatric symptom in those with CIND or MCI
and normal cognition was also lower than this prior study
(44% vs 51% in those with CIND or MCI, 18% vs 27% in
those with normal cognition). Agitation, apathy, and aber-
rant motor behaviors were the most common neuropsychi-


































Figure 1. Total number of neuropsychiatric symptoms according to cognitive category. Prevalence estimates were derived using the
Aging, Demographics, and Memory Study (ADAMS) sample weights to adjust for the complex sampling design of the ADAMS; 95%
confidence intervals are in parentheses.
CIND 5 cognitive impairment without dementia.
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some of the symptoms that these individuals with difficulty
communicating could exhibit and their informants could
observe.
To the authors’ knowledge, this is the first study to
examine the relationship between number of neuropsychi-
atric symptoms and presence of individual symptoms and
ADL and IADL limitations and to considering the clinical
significance of the symptoms and adjust for cognitive cat-
egory, including dementia severity. A greater number of
neuropsychiatric symptoms may lead to ADL and IADL
limitations as a direct consequence of the symptoms them-
selves, or it is possible that neuropsychiatric symptoms are a
reflection of worse cognitive impairment even within cog-
nitive categories. Impairment of executive control func-
tions, which has been suggested as a cause for functional
limitations,40–42 may confound this relationship. Other
physical illnesses, not controlled for in this study, for ex-
ample Parkinson’s disease or limb amputation, may be as-
sociated with neuropsychiatric symptoms (e.g., depression,
psychosis, apathy) and ADL limitations. Regarding the as-
sociation between individual neuropsychiatric symptoms
and functional limitations, the findings were somewhat
different than in prior studies, again probably because of
differences in methodology. Although a prior study found
psychosis (delusions and hallucinations) to be associated
with more-significant functional limitations,25 the current
study found that this relationship was not significant after
adjusting for co-occurring neuropsychiatric symptoms and
chronic medical conditions. Other symptoms that were in-
dependently associated with functional limitations (depres-
sion, anxiety, and aberrant motor behaviors) were identified
when these symptoms were clinically significant.
The strengths of this study include a nationally repre-
sentative population-based sample that included the whole
spectrum of cognitive function and the use of a well-
validated comprehensive assessment of neuropsychiatric
symptoms. A number of potential limitations should also be
considered when interpreting the results. Some remaining
nonresponse bias might have affected the analyses despite
the use of ADAMS sampling weights, which attempted to
account for differential nonresponse. Measurement error
for neuropsychiatric symptoms may have occurred even
though the NPI has been shown to have good psychometric
characteristics.36 ADAMS interviewers assessed the reli-
ability of informants; 83%, 13%, and 1.3% of informants
were rated as very reliable, probably reliable, and not
reliable, respectively. Assessment of functional limitations
may also be subject to measurement error because subop-
timal reliability between informant report and directly ob-
served limitations has been suggested in prior studies.43
In summary, neuropsychiatric symptoms are common
in older adults with CIND and dementia in the United
States and are associated with a significantly higher level of




































































































































































































































































































































Figure 2. Estimated prevalence of individual neuropsychiatric symptoms according to cognitive category. Prevalence estimates were
derived using the Aging, Demographics, and Memory Study (ADAMS) sample weights to adjust for the complex sampling design of
the ADAMS. Whiskers indicate 95% confidence intervals.
Shaded areas in the graphs represent clinically significant symptom (i.e., frequency score by severity score is 4).
CIND 5 cognitive impairment without dementia.
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understanding how neuropsychiatric symptoms affect func-
tion may help in the design of interventions to better man-
age neuropsychiatric symptoms and reduce their burden on
patients, families, and the healthcare system.
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